Communiqués BioLineRx Ltd.

Actions

BLRX

IL0011015182

Marché Fermé - TEL AVIV STOCK EXCHANGE Autres places de cotation 16:24:13 27/06/2024			Varia. 5j.	Varia. 1 janv.
15,3 ^ILa	-1,92%		-4,38%	-59,95%

30/05	BioLineRx Ltd annonce un accord d'essai clinique avec le St. Jude Children's Research Hospital, Inc. pour évaluer le motixafortide pour la mobilisation des cellules souches hématopoïétiques CD34+ pour des applications de thérapie génique dans la drépanocytose.	CI
28/05	Transcript : BioLineRx Ltd., Q1 2024 Earnings Call, May 28, 2024

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapy Applications in Sickle Cell Disease	31/05	AQ
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates	29/05	AQ
BioLineRx : Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates	28/05	PU
BioLineRx to Report First Quarter 2024 Results on May 28, 2024	22/05	PR
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification	20/05	AQ
BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024	06/05	PU
BioLineRx : Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	17/04	PU
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	10/04	PR
BioLineRx Announces $6 Million Registered Direct Offering	02/04	AQ
BioLineRx : Form 20-F/A (Amendment No. 1	28/03	PU
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	27/03	AQ
BioLineRx : Annual Report on Form 20-F FOR 2023	26/03	PU
BioLineRx : Report of Periodic or Interim Report	26/03	PU
BioLineRx : Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	26/03	PU
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024	20/03	PR
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production	04/03	PR
BioLineRx : FORM F-3-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933	31/12	PU
BioLineRx : FORM S-8-registration of Ordinary Shares to be issued under the Plan	31/12	PU
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease	21/12	PR
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates	21/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués BioLineRx Ltd.

Actions

BLRX

IL0011015182

Communiqués

Filtres